Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Jonas Bergh et al.|The Lancet|2014Cited by 4.7k
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) TabletsMartin H. Cohen, Richard Pazdur, Grant A. Williams et al.|The Oncologist|2003Cited by 576
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Richard Pazdur, Gwynn Ison et al.|Clinical Cancer Research|2015Cited by 526
United States Food and Drug Administration Drug Approval SummaryMartin H. Cohen, Richard Pazdur, Grant A. Williams et al.|Clinical Cancer Research|2004Cited by 500
FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable SuspensionEdvardas Kaminskas, Richard Pazdur, Ann T. Farrell et al.|The Oncologist|2005Cited by 488